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Sarcoidosis is a granulomatous disorder of unknown cause, affecting multiple organs, but
mainly the lungs. The exact order of immunological events remains obscure. Reviewing
current literature, combined with careful clinical observations, we propose a model for gran-
uloma formation in pulmonary sarcoidosis. A tight collaboration between macrophages,
dendritic cells, and lymphocyte subsets, initiates the first steps toward granuloma for-
mation, orchestrated by cytokines and chemokines. In a substantial part of pulmonary
sarcoidosis patients, granuloma formation becomes an on-going process, leading to debili-
tating disease, and sometimes death.The immunological response, determining granuloma
sustainment is not well understood. An impaired immunosuppressive function of regula-
tory T cells has been suggested to contribute to the exaggerated response. Interestingly,
therapeutical agents commonly used in sarcoidosis, such as glucocorticosteroids and anti-
TNF agents, interfere with granuloma integrity and restore the immune homeostasis in
autoimmune disorders. Increasing insight into their mechanisms of action may contribute
to the search for new therapeutical targets in pulmonary sarcoidosis.
Keywords: pulmonary sarcoidosis, granuloma, formation, integrity, dendritic cells,T helper 1 cells,T helper 17 cells,
regulatoryT cells
INTRODUCTION
Sarcoidosis is a granulomatous disorder of unknown cause, affect-
ing multiple organs, but mainly the lungs. In 10–30% of the
cases, sarcoidosis becomes chronic and progressive leading to
debilitating disease and sometimes death (1). Its etiology is
intriguing, since a part of its definition (i.e., unknown cause)
makes it uniquely different from granulomatous disorders aris-
ing from exposure to a known chronically persisting antigen,
such as tuberculosis, visceral leishmaniasis, and chronic beryl-
lium disease (2, 3). Nevertheless, several observations support an
antigen-induced disease etiology. First, epidemiological research
identified environmental and occupational risk factors, such as
exposure to musty odors and insecticides (4). Second, infec-
tious agents, including Propionibacterium acnes (P. acnes) and
Mycobacterium tuberculosis (Mtb), have been implicated, since
genomes of these species are detected within sarcoid granu-
lomas (5). A role for mycobacterial peptides is further sup-
ported by the presence of T lymphocytes that are highly respon-
sive toward 6-kDa early secreted antigenic protein (ESAT-6) or
catalase peroxidase (KatG) in the broncho-alveolar lavage fluid
(BALF) of sarcoidosis patients (6–8). Third, a limited clonality of
CD4+ T cells, expressing the AV2S3 T cell receptor, was demon-
strated within the lungs of HLA-DRB1*03 positive sarcoidosis
patients, which is consistent with an antigenic response (9–12).
Finally, evidence for an antigen-induced disease lies within the
granulomatous reaction that is virtually indistinguishable from
sarcoid granulomas and occurs in individuals with sarcoidosis
upon subcutaneous injection of homogenates from allogeneic
sarcoid spleen or lymph nodes (LNs), i.e., the Kveim–Siltzbach
test (13, 14).
GENETIC RISK FACTORS IN SARCOIDOSIS
People all over the world suffer from sarcoidosis (15). Famil-
ial clustering (16), increased concordance in monozygotic twins
(17) and variations in susceptibility and disease presenta-
tion among different ethnic groups (18), suggest the impor-
tance of genetic, next to environmental risk factors in the
etiology.
Genome-wide association studies (GWAS) identified poly-
morphisms within genes coding for proteins involved in T cell
activation, differentiation, proliferation, and survival, including
NOTCH 4 and ANXA11 (19, 20). Additionally, GWAS and case-
control studies identified important genetic risk factors within
the antigen presentation locus at 6p21.3, which contains genes
encoding proteins involved in both antigen presentation and T
cell regulation, including human leukocyte antigen (HLA) and
butyrophilin-like protein (BTNL)-2, respectively (20–23).
Specific HLA class II antigens are associated with certain sar-
coidosis disease phenotypes. For example, the HLA-DRB1*03 and
DQB1*0201 alleles have been associated with an acute disease
onset, Löfgren syndrome and resolving disease, whereas in con-
trast HLA-DRB1*15 and DQB1*0601 are associated with chronic
sarcoidosis (24–27). It is conceivable that both resolving and per-
sistent sarcoidosis arise due to a unique combination of a specific
genetic background and exposure to one or several environmental
triggers (28). This unique combination might lead to persistent
stimulation of the immune system, contributing to granuloma
formation and sustainment.
In this article we review the current knowledge on the role of
the immune activation in pulmonary sarcoidosis and propose a
hypothesis on the origin of granuloma formation. Secondly, we
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aim to discuss granuloma integrity, highlighting areas for research
into new therapeutical targets.
GRANULOMA FORMATION
A well-developed sarcoid granuloma consists of a tightly formed
conglomerate of epithelioid- and multinucleated-giant cells
(MGCs) encircled by lymphocytes, especially CD4+ T helper (Th)
cells, but also rare CD8+ T cells and B cells (1). Both granuloma
formation and integrity depend on the availability and supply of
these different cells (29). The chronological order of immuno-
logical events and the exact role of these cells during the sarcoid
granulomatous response remain obscure, due to the lack of an
animal model for sarcoidosis. Nevertheless, careful clinical obser-
vations and in-depth research on functional properties of different
cells involved provide essential information to unravel the cellular
and molecular mechanisms of granuloma formation.
CLINICAL SIGNS
Cardinal features of pulmonary sarcoidosis are mediastinal lym-
phadenopathy, parenchymal, and airway granulomas, giving rise
to upper lobe nodules in a perilymphatic or bronchovascular dis-
tribution and signs of a CD4+ T cell alveolitis. An interstitial
pneumonitis, found on open lung biopsy, is classically thought to
represent a very early stage of granuloma formation (30). Sponta-
neous remission and reactivation of sarcoidosis makes it difficult
to ascertain the exact sequence of these cardinal features, however
several findings strongly suggest a certain order in the major-
ity of patients, which may add to the hypothesis on granuloma
formation as described below.
Although it is well known that patients do not go through all
disease stages as described by Scadding (from I to IV) sequen-
tially, arguably pulmonary sarcoidosis starts in the draining LN.
As stage I (bihilar lymphadenopathy) is most often asymptomatic,
it is conceivable that it precedes pulmonary involvement, seen
in stage II and III. Additionally, progression of stage I to II dis-
ease is well known, while development of stage I after stage III
is uncommon. Finally, a recent trial found an increased diag-
nostic sensitivity of LN-derived fine needle aspirates, compared
with transbronchial lung biopsies (31). These data suggest that the
first granulomas are formed within the mediastinal LN, only later
followed by granuloma formation within the lungs.
Consequently, LN-specific immune reactions are important in
early sarcoid granuloma formation, such as antigen presentation
by dendritic cells (DCs). DCs are the only cells capable to pick
up antigens and migrate to the LN where they present antigens to
naïve T cells. Hereby they initiate highly specific clonal T cell dif-
ferentiation and proliferation (32). Alternatively, LN-resident DCs
may encounter antigenic particles, which we propose are submi-
croscopic and may therefore have passively migrated through the
afferent lymph. The activated and differentiated Th cells migrate
toward the site of inflammation, orchestrated by chemokines.
Macrophages contribute to early recognition of the putative
sarcoid antigen in the lungs, thereby attracting mononuclear cells,
including monocytes and LN-activated lymphocytes. The ensuing
influx of cells leads to an interstitial pneumonitis, characterized by
a mixed mononuclear cell infiltrate in the alveolar wall and CD4+
T cell alveolitis (30).
At the site of antigen encounter, antigen-presenting cells
(APCs) induce persistent stimulation of the immune response,
mediated by HLA-related proteins, leading to continuous recruit-
ment and local expansion of lymphocytes and eventually granu-
loma formation. The central localization of macrophages within
the final epithelioid aggregate supports an important role in anti-
gen presentation at the site of granuloma formation. Alternatively,
DCs may play a critical role in antigen presentation within the
granuloma. Their capacity for antigen sampling within the lymph
fluid makes them likely candidates to contribute to the induction
of the perilymphatic localized granulomas (33, 34).
In the following paragraphs we describe the current knowl-
edge on the role of macrophages, DCs, and lymphocytes in sarcoid
granuloma formation in more detail, also summarized in Figure 1.
MACROPHAGES
Upon activation, macrophages release nuclear factor (NF)-κB-
dependent pro-inflammatory cytokines, such as interleukin (IL)-1
and tumor necrosis factor-α (TNF-α) (35). In sarcoidosis, BALF
cells and monocytes highly express toll-like receptor (TLR)-2
(36, 37) and produce increased amounts of TNF-α, IL-1β, and
IL-6 compared with controls, when stimulated with TLR-2 lig-
ands, including ESAT-6 and KatG (7, 36–38). A role for TLR-2
in immune activation and granuloma formation in sarcoidosis is
further supported by genetic and mouse studies (38, 39). Lately,
continuous TLR-2 ligation by macrophage-derived serum amyloid
A has been suggested to contribute to persistent stimulation of the
immune response in sarcoidosis (37).
Intrinsically,unstimulated sarcoid-derived alveolar macrophages
(AMs) produce increased amounts of IL-1 and TNF-α (40–43)
and are highly activated (44, 45). The amounts of spontaneously
produced TNF-α by BALF cells in vitro correlate with the pres-
ence of aggregates of AMs in the tissue (46, 47). Only AMs from
patients with active and progressive disease produce increased
amounts of TNF-α (48–51). These data highlight the role of TNF-
α in granuloma formation and integrity, also supported by mouse
studies (52–54).
Important mechanisms of action of TNF-α include
macrophage activation, promotion of cellular migration toward
the site of inflammation and leukocyte adhesion (52, 55, 56). In a
mycobacterial-driven mouse model, TNF-α is responsible for the
early production of chemokines that attract mononuclear cells
to the site of inflammation, such as RANTES, MIP-1α, MIP-1β,
MIP-2, and MCP-1 (55), of which increased amounts are found in
sarcoidosis BALF (57–59). In active sarcoidosis, AMs produce high
amounts of CCL20, when stimulated by TNF-α and IL-1β (60).
CCL20 is a chemokine with high affinity for chemokine recep-
tor CCR6, therefore attracting DCs, B cells, and specific T cell
subsets toward the lungs (60, 61). Similarly, AM-derived CXCL10
and CXCL16 contribute to CXCR3+ and CXCR6+ CD4+ Th cell
recruitment (62, 63).
In a mycobacterial-driven granuloma model, efficient cellu-
lar recruitment, mediated by AM-derived CXCL10 and CXCL16,
depends on interferon-γ (INF-γ) (53). During the early innate
response natural-killer (NK) cells are important producers
of INF-γ, when stimulated by TNF-α, IL-1, and IL-12. In
sarcoidosis, the size of a distinct NK cell subpopulation
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FIGURE 1 | A schematic model for granuloma formation in pulmonary
sarcoidosis. An unknown airborne-antigen activates (A) interstitial
dendritic cells (DCs), (B) alveolar macrophages (AMs), and (C) alveolar
epithelial cells type II (AEC-II) (dark green), simultaneously. This process is
initiated by toll-like receptor-2 (TLR-2) ligands, possibly Mycobacterium
tuberculosis-derived ESAT-6 or mKatG. (A) The interstitial DCs pick up the
putative antigen and migrate toward the mediastinal lymph nodes (LNs),
where they initiate differentiation and clonal expansion of T helper (Th)1 and
17 cells. (B) Simultaneously, AMs produce tumor necrosis factor-α (TNF-α),
which initiates upregulation of activation (HLA-DR and CD80/86) and
adhesion (ICAM-1 and LeuCAM) molecules. Macrophages produce
chemokine ligands (MCP-1, CCL20, CXCL10, and CXCL16) under
stimulation of both TNF-α and natural-killer (NK) cell-derived interferon-γ
(INF-γ), thereby attracting Th1/17 cells, monocytes, regulatory T cells
(Tregs), and B cells. (C) The lung environment is characterized by the
presence of Th1 and Th17 favoring cytokines, such as IL-6, IL-12, IL-18, IL-23,
and TGF-β, produced by macrophages, perilymphatic DCs, and AEC-II.
Persistent stimulation, mediated by antigen presenting cells (APCs), leads
to continuous cellular recruitment to the site of inflammation, which leads
to granuloma formation. Tregs infiltrating the granuloma fail to diminish the
exaggerated immune response, thereby contributing to granuloma
persistence and integrity.
(CD56brightCD94highKIRlow) is increased in the BALF compared
with controls (64). Furthermore, higher proportions of NK cells
were found to correlate with a poor outcome (65).
Once recruited, TNF-α is needed for leukocyte adhesion, since
an abrogation of tightly formed granulomas in TNF-α-deficient
mice is observed following mycobacterial infection (55). In sar-
coidosis, TNF-α induced the expression of intracellular adhe-
sion molecule-1 (ICAM-1) on AMs, leading to cellular aggrega-
tion (66). Additionally, leukocyte adhesion molecule (LeuCAM)
expression, such as CD11a/b/c and CD18 (67), is increased in
sarcoid AMs compared with controls.
Following adhesion, epithelioid histiocytes and monocyte-
derived DCs (moDCs) can fuse to MGCs when stimulated by
local cytokines, such as TNF-α, GM-CSF, IL-17A, CCL20, and INF-
γ (68, 69). Patient-derived macrophages and monocytes show an
enhanced potential to form MGCs in vitro, compared with healthy
controls and other granulomatous diseases (70).
Importantly, sarcoid-derived AMs have an increased acces-
sory function on autologous blood- and lung-derived T lym-
phocytes, when compared with controls (71–73). Macrophages
are not capable to migrate to the LN to induce naive T cell
activation, making them weak APCs. Nonetheless, in sarcoido-
sis, macrophages might contribute to local antigen presentation,
enhancing proliferation of chemokine-recruited memory Th cells.
In summary, macrophages are important for the initial accu-
mulation, aggregation, and fusion of the cellular building blocks
needed for granuloma formation. This process is mediated by the
strong immune modulatory capacities of TNF-α and assisted by
NK cells, which produce INF-γ.
DENDRITIC CELLS
Only a few studies investigated the role of DCs in sarcoid gran-
uloma formation (47, 74). Our group has shown that gran-
uloma formation surrounding intravenously injected antigen-
loaded beads trapped in the lung vasculature is dependent on
DC-initiated Th cell proliferation within the mediastinal LN (75).
In sarcoidosis, an accumulation of mature (Fascin+HLA-DR+DC-
LAMP+) DCs is found surrounding LN granulomas, adjacent
to CD3+ lymphocytes, suggesting DC-T cell interaction at this
site (76). Mature (CD11c+CD86+) DCs are found surrounding
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granulomas in sarcoid-derived mucosal biopsies (77), further sup-
porting a role for DCs in airway and parenchymal granuloma
formation.
An impaired accessory function of ex vivo blood-derived
myeloid DCs (mDCs) has been suggested to contribute to gran-
uloma formation, as clearance of the putative antigen may be
ineffective and the immune system turns to granuloma forma-
tion as a default immunological response (78). In contrast, our
group isolated BALF mDCs of sarcoidosis patients and found
them to be immunocompetent, initiating proliferation of allo-
geneic, naïve T lymphocytes comparable with mDCs from healthy
controls (77). Similarly, in vitro cultured moDCs showed a compa-
rable accessory capacity as controls, although they are intrinsically
prone to produce TNF-α (77, 79). Hence, it is most likely that
DCs are involved in granuloma formation, instead of displaying
diminished antigen-presenting capacities.
Differentiation of T lymphocytes depends on the local
cytokines surrounding the initiating APC (80). Although it is
very likely that LN-specific interactions, mediated by DCs, are
responsible for the initial T cell polarization toward a Th1 and
Th17 phenotype as observed in sarcoidosis, direct evidence is still
lacking.
LYMPHOCYTES
Sarcoidosis is characterized as a Th1- (81) and more recently a
Th17-mediated disease (61, 82), based on the accumulation of
INF-γ, IL-2, and IL17-producing Th cells in the lungs of patients
with active sarcoidosis (44, 61, 82–84).
Th1 differentiation depends on IL-12 and IL-18, which are
increased in BALF of sarcoidosis patients (85, 86). Alveolar
epithelial cells type II (AEC-II) may contribute to this Th1-
favoring environment, since patient-derived AEC-II produce IL-
18 upon TLR-2 stimulation (87, 88). Additionally, AEC-II may
contribute to CXCR3+ Th1 cell recruitment by production of
CXCL10 (89).
Th17 differentiation is driven by IL-6 and TGF-β, both pro-
duced by sarcoid-derived BALF cells (90, 91), whereas survival and
proliferation of this subset is IL-23-dependent (92–94). Increased
expression of the IL-23-receptor and IL-17, both expressed by
Th17 cells, is found in blood-, lung-, and LN-derived lympho-
cytes of active sarcoidosis patients, and not in inactive disease (61,
82). Recently, ESAT-6-specific Th17 cells in the BALF of sarcoido-
sis patients were found (95). Additionally, IL-17A is essential for
granuloma formation in the lung during mycobacterial infection
(96) or in chronic granulomatous disease (97).
We recently found that the proportions of circulating IL-
17A/IFN-γ and IL-17A/IL-4 double-producing cells are signif-
icantly increased in the peripheral blood of patients and are
present in substantial numbers in BALF (82). Findings in sev-
eral autoimmune diseases have indicated the pathogenic potential
of CD4+ Th cells producing both IL-17 and IFN-γ (98, 99).
Processes underlying Th17 cell induction in sarcoidosis remain
obscure, but the presence of these cells can suggest a role for
autoimmune responses in sarcoidosis. B lymphocytes and plasma
cells are found surrounding sarcoid granulomas (100). Addition-
ally, active sarcoidosis patients have increased serum levels of
B-cell-activating factor (BAFF) (101). Since B cell maturation
and function depends on BAFF, its aberrant expression can
initiate defective selection of autoreactive B cells, leading to
autoantibody production (101, 102). In sarcoidosis, approxi-
mately 30–60% of the patients exhibit antinuclear antibody (ANA)
positivity (101, 103).
A SNP in the IL-23 receptor gene has been associated with
chronic sarcoidosis (104), which may contribute to Th17 cell
development in sarcoidosis. Since IL-23 is a heterodimer of the
p19 subunit and the p40 subunit of IL-12 (105) the Th1- and
Th17-promoting cytokines share a common therapeutical target.
Ustekinumab, a neutralizing antibody against the IL-12/IL-23 p40,
was shown to be successful in the Th1/Th17-mediated diseases
psoriasis and Crohn’s disease (CD) (106, 107), but not in chronic
pulmonary or skin sarcoidosis (108, 109).
GRANULOMA INTEGRITY
In the majority of the sarcoidosis patients, granulomas spon-
taneous resolve within several years, without need for therapy.
However, a substantial proportion of the patients develop chronic
progressive disease, whereby granulomas persist and form fibrotic
lesions, leading to debilitating disease, and sometimes death
(1, 110). The immunological response, determining granuloma
sustainment is not well understood.
REGULATORY T CELLS
Regulatory T cells (Tregs) play an important role in diminishing
Th cell specific responses and are pivotal for maintenance of self-
tolerance and immune homeostasis (111). An impaired immuno-
suppressive function of sarcoid-derived Tregs has been suggested
to contribute to the on-going, exaggerated immune response, since
sarcoid blood-derived (CD4+CD25high) Tregs fail to inhibit gran-
uloma growth in an in vitro granuloma culture model (112, 113).
Subsequently, an impaired immunosuppressive function of both
blood- and BALF-derived sarcoidosis Tregs has repetitively been
described on autologous and allogeneic healthy Th cell prolifera-
tion (114–116). These studies also show that sarcoid-derived Tregs
fail to inhibit production of TNF-α, INF-γ, and IL-2, contribut-
ing to granuloma formation, rather than diminishing the immune
response (112, 113, 116). It remains unknown what mechanism(s)
underlies this impaired function.
Active and persisting sarcoidosis was recently associated with
a global CD4+ T cell subset dysfunction (116). Notably, both
Th anergy and Treg malfunctioning were restored in patients
with disease resolution (116). These results highlight the com-
plex interplay between pro-inflammatory and anti-inflammatory
responses needed for granuloma integrity. This fine balance may
explain contradictory results with regard to reported Treg num-
bers in the BALF (112–119) (Table 1). Low BALF Tregs (i.e.,
less immunosuppression) in patients have been associated with
a favorable prognosis in a Scandinavian population (118). In
contrast, a German study reported decreased BALF Treg num-
bers in sarcoidosis patients who develop chronic (active) disease,
when compared with controls and patients who develop sponta-
neous resolution (115). Similarly, CD1d-restricted natural-killer T
(NKT) cells with immunoregulatory function are greatly reduced
in the peripheral blood of all sarcoidosis patients, except Löfgren
patients (120).
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Taken together, these studies imply different roles for immune
regulatory cells in sarcoidosis, either contributing to or preventing
an on-going, exaggerated immune response. Arguably, whereas
in the early sarcoid response there may be no need for Tregs to
inhibit an effective immune response, during persistent stimula-
tion immune regulatory cells should function as a natural brake
on the exaggerated response to prevent immunopathology and
autoimmunity.
INTERFERING WITH GRANULOMA INTEGRITY
Effective treatment agents used for sarcoidosis interfere with gran-
uloma integrity and would ideally prevent fibrogenesis. Gluco-
corticosteroids (GCs), the main stay of sarcoidosis therapy, par-
tially exert their beneficial effect by repression of NF-κB-related
cytokine gene transcription and induction of lymphocyte apop-
tosis (121, 122). Using a mouse model, Tregs are found to be less
sensitive to GC-induced apoptosis compared with Th cells, favor-
ing an anti-inflammatory milieu (123, 124). Similarly, anti-TNF
agents induce monocyte and lymphocyte apoptosis (125–127),
while improving Treg numbers (123). Interestingly, infliximab,
which blocks membrane-bound TNF-α, is uniquely associated
with a high risk of reactivation of latent Mtb infection, whereas
etanercept, solely blocking secreted TNF-α, is not (29). This phe-
nomenon implies a critical role of membrane-bound TNF-α sig-
naling in granuloma integrity (29), which is further supported by
mouse studies (128).
Whether GCs and anti-TNF agents interfere with the delicate
Th/Treg balance in pulmonary sarcoidosis, remains to be eluci-
dated. Research into this field will shed more light on the role
of Tregs in sarcoid pathology and whether Treg induction holds a
promising new therapeutical strategy. Finally, an interplay between
anergic Th cells, IL-10, alternatively activated macrophages (M2),
CCL18 and lung fibroblasts has recently been suggested to con-
tribute to fibrotic remodelling of the lung in chronic sarcoido-
sis (129). These insights yield new therapeutical targets to pre-
vent irreversible organ damage in chronic pulmonary sarcoidosis
patients.
CONCLUSION
Sarcoidosis is an intriguingly complex granulomatous disorder,
characterized by an exaggerated Th1/17 immune response, ini-
tiated by APCs, and maintained due to malfunctioning of Tregs.
Refining insight into immunological events that determine granu-
loma fate may help identify new therapeutical targets and patients
who will benefit such therapy in the future.
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